Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch GALWAY, Ireland--(BUSINESS WIRE)-- Signum Surgical, a medical technology company dedicated to advancing the ...
Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results